UKNIS; Marc E.

Patent Applications and Registrations

Patent applications and USPTO patent grants for UKNIS; Marc E..The latest application filed is for "therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to rna interference molecules".

Company Profile

2.7.10

UKNIS; Marc E. - Chadds Ford PA
Uknis; Marc E. - Livingston NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Therapeutic Alteration Of Transplantable Tissues Through In Situ Or Ex Vivo Exposure To Rna Interference Molecules App 20220119814 - KOWALIK; Timothy F. ; et al.	2022-04-21
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules Grant 11,220,686 - Kowalik , et al. January 11, 2	2022-01-11
Methods Of Treating Antibody-mediated Rejection In Organ Transplant Patients With C1-esterase Inhibitor App 20200360495 - Broom; Colin ; et al.	2020-11-19
Therapeutic Alteration Of Transplantable Tissues Through In Situ Or Ex Vivo Exposure To Rna Interference Molecules App 20200063129 - KOWALIK; Timothy F. ; et al.	2020-02-27
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules Grant 10,260,066 - Kowalik , et al.	2019-04-16
Methods Of Treating Antibody-mediated Rejection In Organ Transplant Patients With C1-esterase Inhibitor App 20180104319 - Broom; Colin ; et al.	2018-04-19
Methods of treating antibody-mediated rejection in organ transplant patients with C1-esterase inhibitor Grant 9,895,428 - Broom , et al. February 20, 2	2018-02-20
Therapeutic Alteration Of Transplantable Tissues Through In Situ Or Ex Vivo Exposure To Rna Interference Molecules App 20160024507 - KOWALIK; Timothy F. ; et al.	2016-01-28
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules Grant 9,150,861 - Kowalik , et al. October 6, 2	2015-10-06
Therapeutic Alteration Of Transplantable Tissues Through In Situ Or Ex Vivo Exposure To Rna Interference Molecules App 20150191731 - KOWALIK; Timothy F. ; et al.	2015-07-09
Methods Of Treating Antibody-mediated Rejection In Organ Transplant Patients With C1-esterase Inhibitor App 20150147319 - Broom; Colin ; et al.	2015-05-28
Methods Of Inhibiting The Alternative Pathway Of Complement Immune System Activation And Compositions Used Therein App 20150104445 - Uknis; Marc E. ; et al.	2015-04-16
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules Grant 8,940,709 - Kowalik , et al. January 27, 2	2015-01-27
Therapeutic Alteration Of Transplantable Tissues Through In Situ Or Ex Vivo Exposure To Rna Interference Molecules App 20130273142 - KOWALIK; Timothy F. ; et al.	2013-10-17
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules Grant 8,361,976 - Kowalik , et al. January 29, 2	2013-01-29
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules App 20060073127 - Kowalik; Timothy F. ; et al.	2006-04-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.